Clinical response rate of 63.5% and clinical remission rate of 30.2% achieved at Week 12 with the highest dose, which continued to improve through Week 28
All three doses met the primary endpoint of clinical response at Week 12, with a favorable safety profile
These results in ulcerative colitis build on strong data recently reported for the plaque psoriasis Phase 3 program
Read More
Three year term includes an accordion of US$5.0 million expansion option to fuel future growth
Lower-cost facility replaces existing debt, reducing servicing costs
Supports operations in both the United States and Canada and enables financing from the United States Export-Import Bank ("EXIM") for Jamestown manufacturing investments
Read More
Funding Under EXIM‘s Make More in America Initiative to Fuel Expansion of Electrovaya's Jamestown Battery Manufacturing Facility
Combination of EXIM Funding with $20 million BMO Credit Facility and $12 Million Equity Capital from December 2024 Provides Electrovaya with Over $80 million for Aggressive U.S. Expansion
Electrovaya has Met Substantially All Condition Precedent Requirements to Drawdown on the EXIM Facility
Read MoreNearly half of patients with moderate-to-severe plaque psoriasis (PsO) treated with icotrokinra achieved completely clear skin (IGA 0) at Week 24 in Phase 3 ICONIC-LEAD study
Topline results from Phase 3 ICONIC-ADVANCE 1&2studies show icotrokinra achieved co-primary endpoints and showed superiority to deucravacitinib in moderate-to-severe PsO
Results pave the way to initiate the first-ever head-to-head study (ICONIC-ASCEND) seeking to demonstrate the superiority of a pill versus injectable biologic in moderate-to-severe PsO
Read MoreUnveiled revolutionary AI Nose for robotics application, inviting global robotics companies to join Ainos Alliance in shaping the future of smell-enabled robots
Advanced VELDONA® development with key Japan patent, Taiwan Tanabe partnership, and IRB approval for Sjögren's syndrome clinical study
Read More
